|
US3862925A
(en)
|
1973-07-05 |
1975-01-28 |
American Home Prod |
Preparation of somatotropin release inhibiting factor and intermediates therefor
|
|
US3842067A
(en)
|
1973-07-27 |
1974-10-15 |
American Home Prod |
Synthesis of(des-asn5)-srif and intermediates
|
|
JPS5726506B2
(cg-RX-API-DMAC7.html)
|
1974-03-08 |
1982-06-04 |
|
|
|
US4105603A
(en)
|
1977-03-28 |
1978-08-08 |
The Salk Institute For Biological Studies |
Peptides which effect release of hormones
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4752601A
(en)
|
1983-08-12 |
1988-06-21 |
Immunetech Pharmaceuticals |
Method of blocking immune complex binding to immunoglobulin FC receptors
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US5985599A
(en)
|
1986-05-29 |
1999-11-16 |
The Austin Research Institute |
FC receptor for immunoglobulin
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
EP0308936B1
(en)
|
1987-09-23 |
1994-07-06 |
Bristol-Myers Squibb Company |
Antibody heteroconjugates for the killing of HIV-infected cells
|
|
JP3095168B2
(ja)
|
1988-02-05 |
2000-10-03 |
エル． モリソン，シェリー |
ドメイン‐変性不変部を有する抗体
|
|
US5169933A
(en)
|
1988-08-15 |
1992-12-08 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
|
US5576184A
(en)
|
1988-09-06 |
1996-11-19 |
Xoma Corporation |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
|
ATE159982T1
(de)
|
1988-09-15 |
1997-11-15 |
Univ Columbia |
Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
|
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
GB8916400D0
(en)
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US5364930A
(en)
|
1990-10-16 |
1994-11-15 |
Northwestern University |
Synthetic C1q peptide fragments
|
|
GB9105245D0
(en)
|
1991-03-12 |
1991-04-24 |
Lynxvale Ltd |
Binding molecules
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US5223408A
(en)
|
1991-07-11 |
1993-06-29 |
Genentech, Inc. |
Method for making variant secreted proteins with altered properties
|
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
US6114147A
(en)
|
1993-02-10 |
2000-09-05 |
Unilever Patent Holdings |
Immobilized proteins with specific binding capacities and their use in processes and products
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
EP0711303B2
(en)
|
1993-07-30 |
2009-06-10 |
Affymax, Inc. |
Biotinylation of proteins
|
|
GB9316989D0
(en)
|
1993-08-16 |
1993-09-29 |
Lynxvale Ltd |
Binding molecules
|
|
AU701302B2
(en)
|
1994-05-13 |
1999-01-21 |
Merck Patent Gesellschaft Mit Beschrankter Haftung |
Improvements in or relating to peptide delivery
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US6300065B1
(en)
|
1996-05-31 |
2001-10-09 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
|
US6699658B1
(en)
|
1996-05-31 |
2004-03-02 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
|
ATE386809T1
(de)
|
1996-08-02 |
2008-03-15 |
Bristol Myers Squibb Co |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
US6025485A
(en)
|
1997-02-14 |
2000-02-15 |
Arcaris, Inc. |
Methods and compositions for peptide libraries displayed on light-emitting scaffolds
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
ATE427966T1
(de)
|
1997-02-11 |
2009-04-15 |
Immunomedics Inc |
Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
DE19721700C1
(de)
|
1997-05-23 |
1998-11-19 |
Deutsches Krebsforsch |
Mutierter OKT3-Antikörper
|
|
BR9908226A
(pt)
|
1998-02-25 |
2000-10-24 |
Lexigen Pharm Corp |
Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
|
|
US6455263B2
(en)
|
1998-03-24 |
2002-09-24 |
Rigel Pharmaceuticals, Inc. |
Small molecule library screening using FACS
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
SE9802213D0
(sv)
|
1998-06-18 |
1998-06-18 |
Amersham Pharm Biotech Ab |
A method for the removal/purification of serum albumins and means for use in the method
|
|
US6727349B1
(en)
|
1998-07-23 |
2004-04-27 |
Millennium Pharmaceuticals, Inc. |
Recombinant anti-CCR2 antibodies and methods of use therefor
|
|
WO2000009560A2
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US7315786B2
(en)
|
1998-10-16 |
2008-01-01 |
Xencor |
Protein design automation for protein libraries
|
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
DE19937264A1
(de)
|
1999-08-06 |
2001-02-15 |
Deutsches Krebsforsch |
F¶v¶-Antikörper-Konstrukte
|
|
ATE373719T1
(de)
|
2000-02-03 |
2007-10-15 |
Millennium Pharm Inc |
Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
|
|
HUP0300919A2
(hu)
|
2000-03-24 |
2003-07-28 |
Micromet Ag |
Többfunkciós polipeptidek NKG2D receptor komplex epitóp kötőhellyel
|
|
EP1294904A1
(en)
|
2000-06-30 |
2003-03-26 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Heterodimeric fusion proteins
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
US20030199671A1
(en)
|
2001-04-18 |
2003-10-23 |
Rondon Isaac Jesus |
Binding molecules for Fc-region polypeptides
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
EP2072059A1
(en)
|
2001-10-12 |
2009-06-24 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
|
ATE481109T1
(de)
|
2001-10-16 |
2010-10-15 |
Us Gov Health & Human Serv |
Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
US20050142539A1
(en)
|
2002-01-14 |
2005-06-30 |
William Herman |
Targeted ligands
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
EP1354600A1
(en)
|
2002-04-19 |
2003-10-22 |
Affimed Therapeutics AG |
Antibody combination useful for tumor therapy
|
|
CA2484182A1
(en)
|
2002-04-29 |
2003-11-13 |
Genpat77 Pharmacogenetics Ag |
Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
|
|
CA2487932A1
(en)
|
2002-05-30 |
2003-12-11 |
Macrogenics, Inc. |
Cd16a binding proteins and use for the treatment of immune disorders
|
|
WO2004001064A2
(en)
|
2002-06-21 |
2003-12-31 |
Dyax Corporation |
Serum protein-associated target-specific ligands and identification method therefor
|
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
ATE536188T1
(de)
|
2002-08-14 |
2011-12-15 |
Macrogenics Inc |
Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
|
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
|
ES2897506T3
(es)
|
2003-01-09 |
2022-03-01 |
Macrogenics Inc |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
EP2052713A3
(en)
|
2003-01-13 |
2009-05-20 |
Macrogenics, Inc. |
Soluble FcgammaR fusion proteins and methods of use thereof
|
|
DE10303664A1
(de)
|
2003-01-23 |
2004-08-12 |
Nemod Immuntherapie Ag |
Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
|
|
CA2523716C
(en)
|
2003-05-31 |
2014-11-25 |
Micromet Ag |
Human anti-human cd3 binding molecules
|
|
CA2531118C
(en)
|
2003-07-01 |
2013-01-08 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
DE10346627A1
(de)
|
2003-10-08 |
2005-05-19 |
Weiss, Stefan, PD Dr. |
Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
PL1706424T3
(pl)
|
2004-01-12 |
2010-04-30 |
Mentrik Biotech Llc |
Warianty regionu Fc
|
|
KR20070004078A
(ko)
|
2004-03-31 |
2007-01-05 |
센토코 인코포레이티드 |
인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도
|
|
DE05733048T1
(de)
|
2004-04-06 |
2007-05-10 |
Affibody Ab |
Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung
|
|
WO2005115452A2
(en)
|
2004-04-16 |
2005-12-08 |
Macrogenics, Inc. |
Fcϝriib-specific antibodies and methods of use thereof
|
|
JP2007536932A
(ja)
|
2004-05-10 |
2007-12-20 |
マクロジェニクス，インコーポレーテッド |
ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
|
|
US7432419B2
(en)
|
2004-05-14 |
2008-10-07 |
Los Alamos National Security, Llc |
Compositions and methods for the treatment of Pierce's disease
|
|
CA2568952C
(en)
|
2004-06-18 |
2019-05-21 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
|
AU2005274905B2
(en)
|
2004-08-04 |
2010-12-23 |
Mentrik Biotech, Llc |
Variant Fc regions
|
|
WO2006044410A2
(en)
|
2004-10-14 |
2006-04-27 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20060193849A1
(en)
|
2005-02-25 |
2006-08-31 |
Antisoma Plc |
Biological materials and uses thereof
|
|
US7988971B2
(en)
|
2005-03-14 |
2011-08-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Human monoclonal antibodies against Hendra and Nipah viruses
|
|
US9296816B2
(en)
|
2005-04-15 |
2016-03-29 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
ES2526811T3
(es)
|
2005-08-10 |
2015-01-15 |
Macrogenics, Inc. |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
|
|
WO2007042261A2
(en)
|
2005-10-11 |
2007-04-19 |
Micromet Ag |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
EP2589654A1
(en)
|
2006-05-03 |
2013-05-08 |
The Regents of the University of Colorado, a body corporate |
CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
|
JP5427027B2
(ja)
|
2006-05-03 |
2014-02-26 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト |
Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
|
|
EP2021029B1
(en)
|
2006-05-26 |
2014-06-11 |
MacroGenics, Inc. |
Humanized fc gamma riib-specific antibodies and methods of use thereof
|
|
ATE490249T1
(de)
|
2007-02-19 |
2010-12-15 |
Glaxosmithkline Llc |
Purinderivate als immunmodulatoren
|
|
AU2008265984B2
(en)
|
2007-06-21 |
2014-07-17 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
EP2210112B1
(en)
|
2007-10-15 |
2012-02-08 |
King's College London |
Diagnostic methods for hiv infection
|
|
MX2010004892A
(es)
|
2007-10-31 |
2010-08-10 |
Scripps Research Inst |
Terapia de combinacion para tratar infecciones virales persistentes.
|
|
US8795667B2
(en)
|
2007-12-19 |
2014-08-05 |
Macrogenics, Inc. |
Compositions for the prevention and treatment of smallpox
|
|
CN102046656A
(zh)
|
2008-03-28 |
2011-05-04 |
航道生物技术有限责任公司 |
针对病毒抗原的中和性分子
|
|
CA2720368C
(en)
|
2008-04-02 |
2017-08-22 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
|
US20110081347A1
(en)
|
2008-06-04 |
2011-04-07 |
Macrogenics, Inc. |
Antibodies with Altered Binding to FcRn and Methods of Using Same
|
|
US20100040601A1
(en)
|
2008-06-10 |
2010-02-18 |
Cantin Edouard M |
Compositions and methods for treating herpes simplex virus infections and related diseases
|
|
MX2011006416A
(es)
|
2008-12-19 |
2011-07-12 |
Macrogenics Inc |
Diacuerpos covalentes y sus usos.
|
|
US8211866B2
(en)
|
2009-01-14 |
2012-07-03 |
Children's Research Institute, Children's National Medical Center |
Methods and compositions for treating HIV infection
|
|
CA2754109A1
(en)
|
2009-03-09 |
2010-09-16 |
Tvax Biomedical, Llc |
Infectious disease cellular immunotherapy
|
|
US20110033389A1
(en)
|
2009-04-29 |
2011-02-10 |
Zhifeng Chen |
Modified antibodies for passive immunotherapy
|
|
PT2438087T
(pt)
|
2009-06-05 |
2017-08-04 |
Ablynx Nv |
Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
|
|
KR20120027055A
(ko)
|
2009-06-26 |
2012-03-20 |
리제네론 파라마큐티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
|
ES2553440T3
(es)
|
2009-08-13 |
2015-12-09 |
Crucell Holland B.V. |
Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
|
|
BR112012007760A2
(pt)
|
2009-10-07 |
2015-08-25 |
Macrogenics Inc |
Método de atenuar fucosilação pós translacional de uma região fc de igc humana, anticorpo que se liga especificamente a um antigeno de câncer caracteristico de um cancêr polipeptideo
|
|
US8999398B2
(en)
|
2009-11-06 |
2015-04-07 |
Transtarget Inc. |
Polyclonal bispecific antibody compositions and method of use
|
|
BR112012012887A2
(pt)
|
2009-12-02 |
2017-05-02 |
Imaginab Inc |
minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
|
|
WO2011085289A1
(en)
|
2010-01-11 |
2011-07-14 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Production of a monoclonal antibody therapeutic against west nile virus in plants
|
|
RU2624027C2
(ru)
|
2010-04-23 |
2017-06-30 |
Дженентек, Инк. |
Получение гетеромультимерных белков
|
|
CN110437320B
(zh)
|
2010-07-09 |
2023-10-20 |
阿菲博迪公司 |
多肽
|
|
EP2601216B1
(en)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
EP4226935A3
(en)
|
2010-08-31 |
2023-09-06 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
|
BR112013010857A2
(pt)
|
2010-11-02 |
2016-09-13 |
Abbott Laboratoires |
imonoglubulinas de duplo domínio variável e usos das mesmas
|
|
CN103649117B
(zh)
|
2011-02-04 |
2016-09-14 |
霍夫曼-拉罗奇有限公司 |
Fc变体及其生成方法
|
|
CN103796677B
(zh)
|
2011-04-20 |
2019-08-16 |
健玛保 |
针对her2和cd3的双特异性抗体
|
|
CN107722124A
(zh)
*
|
2011-05-21 |
2018-02-23 |
宏观基因有限公司 |
能够与人和非人cd3结合的cd3结合分子
|
|
ES2605784T3
(es)
|
2011-05-21 |
2017-03-16 |
Macrogenics, Inc. |
Dominios de enlazamiento a suero desinmunizados y su uso para extender la vida media en suero
|
|
SG10201604279TA
(en)
|
2011-05-27 |
2016-07-28 |
Hoffmann La Roche |
Dual targeting
|
|
WO2013163427A1
(en)
|
2012-04-25 |
2013-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibodies to treat hiv-1 infection
|
|
US9879068B2
(en)
|
2012-06-21 |
2018-01-30 |
California Institute Of Technology |
Antibodies targeting HIV escape mutants
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
US20150239961A1
(en)
*
|
2012-09-26 |
2015-08-27 |
Duke University |
Adcc-mediating antibodies, combinations and uses thereof
|
|
JO3532B1
(ar)
|
2013-03-13 |
2020-07-05 |
Regeneron Pharma |
الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
|
|
EP3839044A1
(en)
|
2013-03-14 |
2021-06-23 |
MacroGenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
WO2015048462A1
(en)
*
|
2013-09-27 |
2015-04-02 |
Duke University |
Human monoclonal antibodies
|
|
RU2718692C2
(ru)
|
2014-05-29 |
2020-04-13 |
Мэкроудженикс, Инк. |
Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
|
|
CU20170041A7
(es)
*
|
2014-09-26 |
2017-09-06 |
Macrogenics Inc |
Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3
|
|
US10717778B2
(en)
|
2014-09-29 |
2020-07-21 |
Duke University |
Bispecific molecules comprising an HIV-1 envelope targeting arm
|